LSE:INDV

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. More Details


Snowflake Analysis

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Indivior's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: INDV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.9%

INDV

-4.3%

GB Pharmaceuticals

-1.0%

GB Market


1 Year Return

129.1%

INDV

3.9%

GB Pharmaceuticals

-14.8%

GB Market

Return vs Industry: INDV exceeded the UK Pharmaceuticals industry which returned 3.9% over the past year.

Return vs Market: INDV exceeded the UK Market which returned -14.8% over the past year.


Shareholder returns

INDVIndustryMarket
7 Day-5.9%-4.3%-1.0%
30 Day-14.5%-8.1%-1.6%
90 Day19.5%-8.9%-3.6%
1 Year129.1%129.1%7.7%3.9%-11.6%-14.8%
3 Year-68.2%-68.2%37.9%22.4%-8.9%-20.2%
5 Year-48.8%-50.5%75.1%41.0%16.2%-10.0%

Price Volatility Vs. Market

How volatile is Indivior's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Indivior undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: INDV (£1.04) is trading below our estimate of fair value (£9.32)

Significantly Below Fair Value: INDV is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: INDV is unprofitable, so we can't compare its PE Ratio to the GB Pharmaceuticals industry average.

PE vs Market: INDV is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate INDV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: INDV is overvalued based on its PB Ratio (17x) compared to the GB Pharmaceuticals industry average (4.5x).


Next Steps

Future Growth

How is Indivior forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

62.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: INDV is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).

Earnings vs Market: INDV is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: INDV's is expected to become profitable in the next 3 years.

Revenue vs Market: INDV's revenue (9.7% per year) is forecast to grow faster than the UK market (6% per year).

High Growth Revenue: INDV's revenue (9.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if INDV's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Indivior performed over the past 5 years?

-19.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: INDV is currently unprofitable.

Growing Profit Margin: INDV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: INDV is unprofitable, and losses have increased over the past 5 years at a rate of 19.9% per year.

Accelerating Growth: Unable to compare INDV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INDV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.8%).


Return on Equity

High ROE: INDV has a negative Return on Equity (-262.07%), as it is currently unprofitable.


Next Steps

Financial Health

How is Indivior's financial position?


Financial Position Analysis

Short Term Liabilities: INDV's short term assets ($1.2B) exceed its short term liabilities ($684.0M).

Long Term Liabilities: INDV's short term assets ($1.2B) exceed its long term liabilities ($809.0M).


Debt to Equity History and Analysis

Debt Level: INDV's debt to equity ratio (406.9%) is considered high.

Reducing Debt: INDV had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: INDV's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: INDV is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet


Next Steps

Dividend

What is Indivior current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate INDV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INDV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INDV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INDV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: INDV is not paying a notable dividend for the UK market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INDV's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Mark Crossley

0.33

Tenure

US$550,800

Compensation

Mr. Mark Crossley has been Chief Executive Officer of Indivior PLC since June 29, 2020 and served as its Chief Financial and Operations Officer since July 29, 2019 until June 29, 2020. He was Chief Financ ...


CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD0.00) is below average for companies of similar size in the UK market ($USD1.15M).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Mark Crossley
CEO & Executive Director0.33yrUS$550.80k0.047%
$ 360.5k
Ryan Preblick
Interim CFO and Senior VP of Global Financial Planning & Analysis Commercial Operations0.33yrno datano data
Christian Heidbreder
Chief Scientific Officerno datano data0.060%
$ 456.5k
Jason Thompson
Vice President of Investor Relationsno datano datano data
Javier Rodriguez
Chief Legal Officerno datano data0.058%
$ 439.2k
Cynthia Cetani
Chief Integrity & Compliance Officer2yrsno datano data
Jon Fogle
Chief Human Resources Officer6yrsno data0.034%
$ 259.1k
Richard Simkin
Chief Commercial & Strategy Officerno datano data0.083%
$ 632.8k
Sue Learned
Senior Vice President of Global Clinical Developmentno datano datano data
Hillel West
Chief Manufacturing & Supply Officer0.58yrno datano data
Kathryn Hudson
Company Secretary5.33yrsno datano data

1.3yrs

Average Tenure

Experienced Management: INDV's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Mark Crossley
CEO & Executive Director0.33yrUS$550.80k0.047%
$ 360.5k
Graham Hetherington
Independent Non-Executive Director0.92yrno data0.0068%
$ 52.0k
Daniel Phelan
Independent Non-Executive Director5.92yrsno data0.015%
$ 114.7k
Peter James Bains
Independent Non-Executive Director1.17yrsno data0.0074%
$ 56.1k
Daniel Tassé
Interim Independent Chairman of the Board & Senior Independent Director0.33yrno data0.0018%
$ 13.5k
Lorna Parker
Independent Non-Executive Director5.92yrsno data0.0035%
$ 26.9k
A. McLellan
Independent Non-Executive Director5.92yrsno data0.0010%
$ 7.9k

3.7yrs

Average Tenure

62yo

Average Age

Experienced Board: INDV's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Indivior PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Indivior PLC
  • Ticker: INDV
  • Exchange: LSE
  • Founded: 2014
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£762.845m
  • Shares outstanding: 733.50m
  • Website: https://www.indivior.com

Number of Employees


Location

  • Indivior PLC
  • 10710 Midlothian Turnpike
  • North Chesterfield
  • Virginia
  • 23235
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INDVLSE (London Stock Exchange)YesOrdinary SharesGBGBPDec 2014
INDVLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBGBPDec 2014
IZQV.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2014
INDV NBMV (Bolsa Mexicana de Valores)YesOrdinary SharesMXMXNDec 2014
INVV.YOTCPK (Pink Sheets LLC)SPONSORED ADRUSUSDDec 2014
2IVADB (Deutsche Boerse AG)SPONSORED ADRDEEURDec 2014

Biography

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company’s product pipeline focuses on trea ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 22:20
End of Day Share Price2020/10/20 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.